Data Insights

Izalontamab by Systimmune for Colon Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Colon Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Colon Cancer

Data Insights

Izalontamab by Systimmune for Hypopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Hypopharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Laryngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Laryngeal Cancer

Data Insights

Izalontamab by Systimmune for Nasopharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Nasopharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Oropharyngeal Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oropharyngeal Cancer

Data Insights

Izalontamab by Systimmune for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Oral Cavity (Mouth) Cancer

Data Insights

Izalontamab by Systimmune for Lung Adenocarcinoma: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Lung Adenocarcinoma

Data Insights

Izalontamab by Systimmune for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Izalontamab by Systimmune for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Recurrent Head And Neck Squamous Cell Carcinoma

Data Insights

Izalontamab by Systimmune for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Izalontamab by Systimmune for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Izalontamab is under clinical development by Systimmune and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Izalontamab in Esophageal Squamous Cell Carcinoma (ESCC)